[Edaily Starin Gim Ga Yeong Reporter] With TV personality Yoo Jae-suk canceling a recording for the first time in 35 years, attention is now focused on when he will return to the set. Yoo Jae-suk (Photo = E-Daily DB) According to his agency, Antenna, on the 22nd, Yoo Jae-suk had to cancel the recording of SBS’s *Whenever I Get a Chance* due to a temporary high fever caused by a cold. Yoo Jae-suk currently appears on SBS’s “Whenever I Get the Chance,” as well as “Running Man,” MBC’s “What Do You Do When You’re Bored?,” tvN’s “You Quiz on the Block,” KBS2’s “Happy Together,” and the YouTube channel “Pinggye-go.” Attention is now focused on when he will return to the set. However, his agency has not disclosed a specific return date. His agency explained, “He is currently focusing on his recovery, and we have asked for the understanding of those involved and are coordinating a reschedule for the recording.” On the same day, MyDaily reported that Yoo Jae-suk, while preparing to film SBS’s “Whenever I Get a Chance” near Jongno, Seoul, informed the production staff of his health condition just before filming was set to begin, and the shoot was ultimately canceled. It is reported that Yoo Jae-suk notified the production staff in advance, before filming began, out of concern that filming while unwell might cause them trouble. This is reportedly the first time Yoo Jae-suk has canceled a recording on the day of filming since his debut in the 1st KBS University Comedy Festival in 1991—a span of 35 years. “Whenever I Get a Chance” is a variety show that focuses on “seizing the moment” to deliver good fortune during the brief gaps of free time encountered in everyday life. Yoo Jae-suk and Yoo Yeon-seok serve as the show’s hosts.
This week (October 6–8), startups across various sectors—including defense, biotech, and artificial intelligence (AI) image-generation platforms—secured investments from venture capital (VC) firms and…
South Korean diagnostic stocks, including Humasis, GC Green Cross MS, and Genematrix, rallied on Tuesday as investors reacted to a suspected plague exposure incident at a Russian research institute.Th…
Yuhan(000100)Overseas clinical trials for “YH32367” (nesprotamig), a bispecific antibody anticancer drug being developed by the company as a “post-Lecraza” (generic name: lazertinib) candidate, are be…